Associations Between MMPI-3 and CAPE Scores: Measuring Psychosis Symptoms in a Non-Clinical Population

Advisor(s)

Andrew J. Kremyar

Confirmation

1

Document Type

Poster

Location

ONU McIntosh Center; Activities Room

Start Date

24-4-2026 10:00 AM

End Date

24-4-2026 10:50 AM

Abstract

Psychosis includes two major types of symptoms: positive (i.e., hallucinations, delusions, paranoia) and negative (i.e., flat affect, poverty of speech, lack of motivation). Psychosis is also frequently comorbid with depressive and other mood disorder symptoms. Differentiating positive, negative, and depression symptoms is important, as practicing clinicians may tailor treatments to specific presenting symptoms. The Minnesota Multiphasic Personality Inventory-3 (MMPI-3) is a broadband measure of personality and psychopathology that includes scales that measure both psychosis and depression related symptoms. Prior studies indicate that scale scores on previous versions of the MMPI-3 can help with the differential diagnosis of depressive and psychosis-related disorders, but there remains a need to examine the ability of the updated MMPI-3 to differentiate these symptoms. Thus, the goal of the current study was to examine the differential prediction of these psychosis symptom dimensions, as measured by the Community Assessment of Psychic Experiences (CAPE), with the MMPI-3 scale scores. A sample of 183 undergraduate students completed the MMPI-3 and CAPE, among a battery of other measures. Zero-order correlations between MMPI-3 and CAPE scale scores were calculated. Regression analyses were used to identify the strongest predictor of each CAPE scale. Results indicated that, when considered by scale family, MMPI-3 scale scores predicted large amounts of variance in CAPE scores, with theoretically relevant MMPI-3 scales emerging as the strongest predictors of each symptom dimension. In summation, results of the current study indicate that the MMPI-3 can predict and differentiate psychosis and depressive symptoms across different scales in a non-clinical sample. Future research directions, limitations, and implications are discussed.

This document is currently not available here.

Restricted

Available to ONU community via local IP address and ONU login.

Share

COinS
 
Apr 24th, 10:00 AM Apr 24th, 10:50 AM

Associations Between MMPI-3 and CAPE Scores: Measuring Psychosis Symptoms in a Non-Clinical Population

ONU McIntosh Center; Activities Room

Psychosis includes two major types of symptoms: positive (i.e., hallucinations, delusions, paranoia) and negative (i.e., flat affect, poverty of speech, lack of motivation). Psychosis is also frequently comorbid with depressive and other mood disorder symptoms. Differentiating positive, negative, and depression symptoms is important, as practicing clinicians may tailor treatments to specific presenting symptoms. The Minnesota Multiphasic Personality Inventory-3 (MMPI-3) is a broadband measure of personality and psychopathology that includes scales that measure both psychosis and depression related symptoms. Prior studies indicate that scale scores on previous versions of the MMPI-3 can help with the differential diagnosis of depressive and psychosis-related disorders, but there remains a need to examine the ability of the updated MMPI-3 to differentiate these symptoms. Thus, the goal of the current study was to examine the differential prediction of these psychosis symptom dimensions, as measured by the Community Assessment of Psychic Experiences (CAPE), with the MMPI-3 scale scores. A sample of 183 undergraduate students completed the MMPI-3 and CAPE, among a battery of other measures. Zero-order correlations between MMPI-3 and CAPE scale scores were calculated. Regression analyses were used to identify the strongest predictor of each CAPE scale. Results indicated that, when considered by scale family, MMPI-3 scale scores predicted large amounts of variance in CAPE scores, with theoretically relevant MMPI-3 scales emerging as the strongest predictors of each symptom dimension. In summation, results of the current study indicate that the MMPI-3 can predict and differentiate psychosis and depressive symptoms across different scales in a non-clinical sample. Future research directions, limitations, and implications are discussed.